Entrada Therapeutics (TRDA) Operating Income: 2022-2025
Historic Operating Income for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$47.1 million.
- Entrada Therapeutics' Operating Income fell 117.25% to -$47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.6 million, marking a year-over-year decrease of 310.37%. This contributed to the annual value of $47.0 million for FY2024, which is 1586.75% up from last year.
- As of Q3 2025, Entrada Therapeutics' Operating Income stood at -$47.1 million, which was down 0.43% from -$46.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Operating Income ranged from a high of $53.4 million in Q2 2024 and a low of -$47.1 million during Q3 2025.
- In the last 3 years, Entrada Therapeutics' Operating Income had a median value of -$5.9 million in 2024 and averaged -$6.5 million.
- Data for Entrada Therapeutics' Operating Income shows a peak YoY increase of 465.28% (in 2024) and a maximum YoY decrease of 254.57% (in 2024) over the last 5 years.
- Quarterly analysis of 4 years shows Entrada Therapeutics' Operating Income stood at -$25.6 million in 2022, then skyrocketed by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then plummeted by 117.25% to -$47.1 million in 2025.
- Its Operating Income was -$47.1 million in Q3 2025, compared to -$46.8 million in Q2 2025 and -$21.8 million in Q1 2025.